Our Pricing

Orlistat vs Wegovy: UK Prescription Weight Loss Options

Published on: June 03, 2026

Choosing between orlistat vs Wegovy UK prescription weight loss treatments can be challenging when both are licensed by the MHRA for obesity management. At Cured Pharmacy, our UK-registered clinical team helps you understand the key differences between these medications, ensuring you receive the most appropriate treatment based on your individual health profile and weight loss goals.

How Orlistat and Wegovy Work Differently

Orlistat and Wegovy represent fundamentally different approaches to weight management. Orlistat (also marketed as Xenical) works locally in your digestive system by blocking approximately 30% of dietary fat absorption through lipase enzyme inhibition [1]. The unabsorbed fat passes through your system, which means orlistat requires careful dietary management to minimise gastrointestinal side effects.

Wegovy contains semaglutide, a GLP-1 receptor agonist that works systemically by mimicking a natural gut hormone. It slows gastric emptying, reduces appetite signals in the brain, and enhances feelings of fullness after meals [2]. Unlike orlistat's local action, Wegovy affects multiple pathways involved in appetite regulation and glucose metabolism, which explains its significantly greater efficacy in clinical trials.

The mechanism difference means orlistat requires three daily doses with meals, whilst Wegovy is administered as a single weekly subcutaneous injection. This dosing convenience often improves treatment adherence, particularly for patients with busy schedules or those who struggle with multiple daily medications.

Clinical Trial Results: Orlistat vs Wegovy Efficacy

The efficacy gap between these treatments is substantial. In the landmark STEP 1 trial, adults using Wegovy achieved an average 14.9% body weight reduction over 68 weeks, with 86% of participants losing at least 5% of their initial weight [2]. By comparison, orlistat trials typically show average weight loss of 3-5% over 12 months when combined with dietary modification [1].

The STEP 2 trial specifically examined semaglutide in patients with type 2 diabetes, demonstrating average weight loss of 9.6% compared to 3.4% with placebo over 68 weeks [3]. Orlistat studies in diabetic populations show more modest results, typically achieving 2-4% weight reduction. For patients requiring significant weight loss to address obesity-related health complications, this efficacy difference can be clinically meaningful.

It's important to note that all clinical trial results represent averages, and individual responses vary considerably. Your UK prescriber will consider your medical history, current medications, previous weight loss attempts, and specific health goals when recommending the most appropriate treatment. Both medications require commitment to lifestyle changes for optimal results.

Real-World Effectiveness Considerations

Clinical trial conditions don't always reflect real-world usage. Orlistat's effectiveness depends heavily on dietary compliance—patients must follow a reduced-calorie, lower-fat diet to minimise side effects and maximise results. Wegovy's appetite-suppressing effects may make dietary adherence easier for some patients, though gastrointestinal side effects during dose escalation require careful management.

Side Effects and Tolerability Profiles

Orlistat's side effects are predominantly gastrointestinal and directly related to its mechanism of action. Common effects include oily spotting, flatulence with discharge, fatty or oily stools, and increased bowel movement frequency [1]. These effects typically worsen when patients consume meals high in fat, which serves as a behavioural deterrent but can impact quality of life and social situations.

Wegovy's side effect profile differs considerably. The most common adverse effects are nausea (44% of patients in trials), diarrhoea (30%), vomiting (24%), and constipation (24%), particularly during dose escalation [2]. These effects are usually mild to moderate and tend to decrease over time as your body adjusts. The gradual dose titration protocol—starting at 0.25mg weekly and increasing over 16-20 weeks—helps minimise gastrointestinal intolerance.

Both medications have important contraindications. Orlistat should not be used during pregnancy or in patients with chronic malabsorption syndrome or cholestasis. Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4]. Your UK prescriber will assess your complete medical history during consultation to ensure treatment safety.

Managing Side Effects Effectively

With orlistat, following a diet containing approximately 30% of calories from fat significantly reduces gastrointestinal side effects. For Wegovy users, eating smaller portions, avoiding high-fat meals, and staying well-hydrated can help manage nausea. Our clinical team at Cured Pharmacy provides detailed guidance on side effect management as part of your ongoing care.

Cost Comparison and UK Availability

Wegovy is available at Cured Pharmacy with transparent upfront pricing. Treatment cost varies based on your prescribed dose, which your UK prescriber determines during clinical assessment. At Cured Pharmacy, Wegovy starts from £79.00 per month, significantly lower than typical market rates for this licensed medication.

Orlistat is available both on prescription and over-the-counter at lower strength (60mg). Prescription-strength orlistat (120mg) requires clinical assessment by a UK prescriber, whilst the lower-strength version can be purchased directly from pharmacies for appropriate patients. The lower acquisition cost of orlistat makes it accessible, though the reduced efficacy compared to GLP-1 treatments means some patients may ultimately spend more time achieving their weight loss goals.

Both treatments are prescription-only medications at therapeutic doses and require ongoing clinical monitoring. At Cured Pharmacy, your initial consultation is free and takes under three minutes to complete. Our UK-registered prescribers review your medical history, current medications, and weight loss goals to recommend the most clinically appropriate and cost-effective treatment for your individual circumstances.

Who Should Choose Orlistat vs Wegovy?

Orlistat may be more suitable for patients who prefer oral medication over injections, have contraindications to GLP-1 receptor agonists, or have a BMI just above the treatment threshold where modest weight loss may be sufficient. It's also appropriate for patients who want to avoid systemic medications and prefer a treatment that works locally in the digestive system.

Wegovy is typically recommended for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities who require more substantial weight loss [4]. It may be particularly suitable for patients with type 2 diabetes, as semaglutide also improves glycaemic control. The once-weekly dosing schedule appeals to patients who struggle with daily medication adherence or prefer fewer dosing occasions.

Your choice should also consider your previous weight loss experience. If you've tried orlistat or similar treatments with limited success, Wegovy's enhanced efficacy profile may offer better outcomes. Conversely, if you've experienced significant nausea with previous medications or have concerns about injectable treatments, orlistat might be preferable despite its more modest efficacy. Our superintendent pharmacist Tarun Kumar and clinical team can discuss these considerations during your consultation.

Combination with Lifestyle Modifications

Neither medication is a standalone solution. Both orlistat and Wegovy are licensed as adjuncts to reduced-calorie diet and increased physical activity. Clinical trials demonstrating their efficacy included structured lifestyle intervention programmes. Patients who combine medication with sustainable dietary changes and regular physical activity achieve the best long-term outcomes.

Getting Started with Weight Loss Treatment at Cured Pharmacy

Starting your orlistat vs Wegovy UK prescription journey at Cured Pharmacy is straightforward. Complete our free online consultation—it takes under three minutes and covers your medical history, current medications, weight loss goals, and any previous treatments you've tried. Our UK-registered prescribers review every consultation individually, ensuring personalised clinical decision-making rather than automated approvals.

If treatment is deemed appropriate and safe, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) and dispatched in 100% discreet packaging with next-day delivery options available. We supply only genuine UK-licensed medications sourced through legitimate pharmaceutical supply chains, never grey-market imports or unlicensed alternatives.

Ongoing support is essential for weight loss success. Our clinical team remains available throughout your treatment for questions about dosing, side effect management, or treatment adjustments. We encourage regular weight monitoring and can adjust your treatment plan based on your progress and tolerability. If you're ready to compare orlistat vs Wegovy UK prescription options with expert guidance, start your free assessment today.

Scientific References

1. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to lifestyle modifications.